Purpose: We generated lung morphometry measurements using single-breath diffusion-weighted MRI and three different acinar duct models in healthy participants and patients with emphysema stemming from chronic obstructive lung disease (COPD) and alpha-1 antitrypsin deficiency (AATD).
Methods: Single-breath-inhaled He MRI with five diffusion sensitizations (b-value = 0, 1.6, 3.2, 4.8, and 6.4 s/cm ) was used, and signal intensities were fit using a cylindrical and single-compartment acinar-duct model to estimate MRI-derived mean linear intercept (L ) and surface-to-volume ratio (S/V). A stretched exponential model was also developed to estimate the mean airway length and L .
Results: We evaluated 42 participants, including 15 elderly never-smokers (69 ± 5 years), 12 ex-smokers without COPD (67 ± 11 years), 9 COPD ex-smokers (80 ± 6 years), and 6 AATD patients (59 ± 6 years). In the never- and ex-smokers, the diffusing capacity of the lung for carbon monoxide (DL ) and computed tomography relative area of less than -950 Hounsfield units (RA ) were normal, but these were abnormal in the COPD and AATD patients, which is reflective of emphysema. Although cylindrical and stretched-exponential-model estimates of L and S/V were not significantly different, the single-compartment-model estimates were significantly different (P < 0.05) for the never- and ex-smoker subgroups. All models estimated significantly worse L and S/V in the AATD and COPD subgroups compared with the never- and ex-smokers without emphysema.
Conclusions: Differences in airspace enlargement may be estimated using L and S/V, generated using MRI and a stretched-exponential or cylindrical model of the acinar ducts. Magn Reson Med 79:439-448, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mrm.26642 | DOI Listing |
J Chromatogr Sci
January 2025
School of Pharmacy, Shanghai University of Medicine and Health Sciences, 279 Zhouzhu Road, Pudong New District, Shanghai 201318, China.
As a traditional Chinese medicine, Sanao decoction (SAD) has been used to treat chronic obstructive pulmonary disease (COPD) for multi-years. However, the potential mechanism and targets for its effects of SAD remain unknown. The 94 components of SAD were identified by UPLC-LTQ-Orbitrap MS.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Public Health, Policy and Systems, University of Liverpool, Liverpool, United Kingdom.
Introduction: Undiagnosed chronic disease has serious health consequences, and variation in rates of underdiagnosis between populations can contribute to health inequalities. We aimed to estimate the level of undiagnosed disease of 11 common conditions and its variation across sociodemographic characteristics and regions in England.
Methods: We used linked primary care, hospital and mortality data on approximately 1.
J Eval Clin Pract
February 2025
Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman, Jordan.
Background: Chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) may deteriorate into acute exacerbations requiring hospitalization. Assessing the predictors of prolonged hospital stays could help identify potential interventions to reduce the burden on patients and healthcare systems.
Aim: This study aimed to identify the risk factors attributed to prolonged hospital stays among patients admitted with acute exacerbations of chronic respiratory disorders in Jordan.
Sleep Breath
January 2025
Department of Internal Medicine II (Cardiology, Pneumology, and Intensive Care), University Medical Centre Regensburg, Regensburg, Germany.
Purpose: In heart failure (HF) and chronic obstructive pulmonary disease (COPD) populations, sleep-disordered breathing (SDB) is associated with impaired health outcomes. We evaluated whether in patients with HF, concomitant HF and COPD or COPD, the number of hospitalizations would be reduced in the year after testing for SDB with and without treatment initiation compared to the year before.
Methods: We performed a multicentre retrospective study of 390 consecutive sleep-clinic patients who had a primary diagnosis of chronic HF, HF and COPD or COPD and a secondary diagnosis of SDB.
Rev Med Suisse
January 2025
Faculté de biologie et médecine, Université de Lausanne, 1005 Lausanne.
In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!